going to do that? are they still going to have the funds that are going to come in to do that? you have to question the guy s whole motive. if you re saying $50 million to $60 million to acquire it. and we re talking about a drug, i guess it s about 10,000 people that use this drug regularly, with it sounds like he probably can t bring it down that much without now losing a ton of money. and shkreli was also saying a couple handful of thousand of people who take this drug. and it is a very rarely used drug, be that doesn t mean that it s not important for those folks. it s very questionable where this price will end up and i hope he s very transparent about where he does price it. dr. cory a. bear, let me bring you in. that justification he offered, and we hear this a lot about one of the great things about the united states is innovation in pharmaceuticals. we re able to come up with these drugs that deal with niche diseases, niche problems, and you need money to go into researc